welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Marina Biotech Announces $1.1 MM Convertible Preferred Stock Financing
Marina Biotech, Inc. ( OTCQB : MRNA ), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the company has entered into a definitive agreement with existing investors, led by Steven T. Newby and James H. Stebbins, for the issuance of convertible preferred stock at a conversion price equivalent to $0.40 per share of common stock resulting in gross proceeds to the company of $1.1 million. In addition, the Company will issue to the investors warrants to purchase up to 3,437,500 shares of common stock. The warrants will have an exercise price of $0.40 per share and are exercisable for a period of six years after the date of issuance. The offering is expected to close on or about August 7, 2015, subject to the satisfaction of customary closing conditions.

expertly curated content related to this topic
- @Joann_458I have familial adenomatous polyposis, s...
- @mzstokesNothing special to see here. Just a regu...
- Barnabas HealthAt this hospital, laparoscopic treatment...
- Siteman Cancer CenterSiteman Cancer Center's specialized onco...
- Vanderbilt University Medical CenterSpeciality ClinicPatient Resources: ...
- Ryan Lee Holland Cancer Foundation, Inc.The Ryan Lee Holland Cancer Foundation, ...
- Hermann Kessler, MD, PhDHermann Kessler, M.D, Ph.D, F.A.C.S is c...